Comparison of Lasmiditan 200 mg Versus 100 mg for Migraine Patients: A Meta-analysis of Randomized Controlled Studies

Author:

Zhong Chuan,Zhang Xuanqin,Qin Guoyong,Wu Jixiang,Tian Yongpan

Abstract

Introduction The ideal dose of lasmiditan for migraine is not clear. This meta-analysis aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. Methods We have searched several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library Databases and selected the randomized controlled trials comparing the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. This meta-analysis was conducted using the random-effect model. Results Five randomized controlled trials were included in this meta-analysis. Compared with lasmiditan 100-mg group in migraine patients, lasmiditan 200-mg group was associated with substantially increased pain free at 2 hours (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.12–1.44; P = 0.0002) and pain free at 24 hours (OR, 1.31; 95% CI, 1.08–1.60; P = 0.007) but demonstrated no obvious impact on pain relief at 2 hours (OR, 1.02; 95% CI, 0.91–1.16; P = 0.72) or MBS free at 2 hours (OR, 0.94; 95% CI, 0.77–1.14; P = 0.52). In addition, the incidence of adverse events was higher in lasmiditan 200-mg group than that in lasmiditan 100-mg group (OR, 1.29; 95% CI, 1.15–1.45; P < 0.0001). Conclusions Lasmiditan 200 mg is better for the treatment of migraine patients than lasmiditan 100 mg.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Reference31 articles.

1. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants;J Neurol Sci,2017

2. Migraine;Nat Rev Dis Primers,2022

3. A rational approach to migraine diagnosis and management in primary care;Ann Med,2021

4. Lasmiditan mechanism of action—review of a selective 5-HT(1F) agonist;J Headache Pain,2020

5. Migraine: beyond pain;Pract Neurol,2021

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3